Disposition of atorvastatin, rosuvastatin, and simvastatin in Oatp1b2 -/- mice and intraindividual variability in human subjects

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1689-1697

  Degorter, M K ^a,b   Urquhart, B L ^a,b   Gradhand, U ^b   Tirona, R G ^a,b   Kim, R B ^b,c  

^a Department of Physiology and Pharmacology ^*  (Canada)

^b Division of Clinical Pharmacology   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

intraindividual variability; Slco1b2 mice; Statin pharmacokinetics

Indexed keywords

ATORVASTATIN; ORGANIC ANION TRANSPORTER 1; ROSUVASTATIN; SIMVASTATIN;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PREDICTION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANIMALS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES; YOUNG ADULT;

EID: 84868029563     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011422815     Document Type: Article

References (25)

1. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006 ; 112: 71-105 (Pubitemid 44301483)
2. Tirona RG, Kim RB Drug Transporters. You G Morris ME, ed. Hoboken, NJ: John Wiley ; 75-104.
3. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 ; 25: 1191-1199 (Pubitemid 27446590)
4. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 ; 28: 1369-1378
5. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001 ; 87 (5A). 28B - 32B (Pubitemid 32274242)
6. McCormick AD, McKillop D, Butters CJ, et al. ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol. 2000 1055 ; 40 :
7. Zaher H, zu Schwabedissen HE, Tirona RG, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol. 2008 ; 74: 320-329
8. Chen C, Stock JL, Liu X, et al. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos. 2008 ; 36: 1840-1845
9. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 ; 87: 130-133
10. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005 ; 280: 9610-9617 (Pubitemid 40409657)
11. van de, Steeg E, Wagenaar E, van der Kruijssen CM, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest. 2010 ; 120: 2942-2952
12. Van de, Steeg E, van Esch A, Wagenaar E, et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res. 2010 ; 17: 294-301
13. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007 ; 82: 726-733 (Pubitemid 350114817)
14. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003 ; 56: 120-124 (Pubitemid 36886497)
15. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003 ; 25: 2822-2835 (Pubitemid 37510592)
16. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 ; 130: 1793-1806
17. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 ; 36: 2014-2023
18. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 ; 15: 513-522 (Pubitemid 41017600)
19. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl- CoA reductase inhibitor transporters. J Biol Chem. 1999 ; 274: 37161-37168
20. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 ; 33: 537-546 (Pubitemid 40393197)
21. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 ; 16: 873-879 (Pubitemid 44772805)
22. Hochman JH, Pudvah N, Qiu J, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 ; 21: 1686-1691 (Pubitemid 41184401)
23. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009 ; 150: 858-868
24. Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011 ; 89: 210-216
25. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001 ; 11: 781-791 (Pubitemid 33151513)